Pegasus Imaging wins OEM dealsCompression developer Pegasus Imaging has added two OEM agreements to its portfolio. Siemens Health Services and Siemens Medical Engineering Group of Erlangen, Germany, have chosen the vendor’s wavelet image
Compression developer Pegasus Imaging has added two OEM agreements to its portfolio. Siemens Health Services and Siemens Medical Engineering Group of Erlangen, Germany, have chosen the vendors wavelet image compression technology, as well as its lossless JPEG and lossy JPEG compression tools, for the PACS vendors Sienet PACS product line.
Pegasus of Tampa, FL, has also entered into a partnership with framegrabber firm Foresight Imaging. Under the terms of the deal, the two companies will co-market Pegasus PICTools Medical Compression Toolkit and Foresights I-Series framegrabbers. By combining Foresights I-50 framegrabber with Pegasus PICVideo codec and PICTools Medical Toolkit, users can capture and compress 1024 x 1024-pixel, 8-bit gray-scale, real-time, 30-frames-per-second video with a Pentium III processor, according to Chelmsford, MA-based Foresight.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.